Drugs / HM10760A
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01013064 | Nov 2009 → Dec 2010 | — | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 1 | NCT01030315 | Oct 2009 → Dec 2010 | — | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2009-09-22 | Hanmi Pharmaceutical Company Limited | Regulatory <보도자료> 한미약품 'LAPS-EPO', 미국 FDA 임상승인 hanmi.co.kr ↗
한미약품이 개발 중인 차세대 빈혈치료 신약 'LAPS-EPO(HM10760A)'에 대한 1상 임상시험을 미국 FDA가 17일 최종 승인했다. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2009-09-22 | Hanmi Pharmaceutical Company Limited | <보도자료> 한미약품 'LAPS-EPO', 미국 FDA 임상승인 hanmi.co.kr ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HM10760A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01013064 ↗ |
| Modality | Protein / enzyme biologic | “Long-acting Erythropoietin (EPO)” NCT01013064 ↗ |
| Route | Intravenous | “single intravenous doses of HM10760A” NCT01013064 ↗ |